{"url_path":"/sec/dwtx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-061938-index.html","accession_number":"0001104659-26-061938","cik":"0001818844","ticker":"DWTX","issuer_name":"Dogwood Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-061938-index.html","primary_entity_key":"0001818844","primary_entity_name":"Dogwood Therapeutics, Inc."},"word_count":70,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\nOn January 11, 2026, pursuant to the Private Offering, the Company agreed to sell to the Investor (i) Pre-funded Warrants to purchase up to 2,047,089 shares of Common Stock and (ii) Common Stock Warrants to purchase up to 4,386,037 shares of Common Stock at a combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant.\n\n​"}